Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes

被引:8
|
作者
Chen, Juan [1 ]
Pang, Aiming [1 ]
Zhao, Yuanqi [1 ]
Liu, Li [1 ]
Ma, Runzhi [1 ]
Wei, Jialin [1 ]
Chen, Xin [1 ]
He, Yi [1 ]
Yang, Donglin [1 ]
Zhang, Rongli [1 ]
Zhai, Weihua [1 ]
Ma, Qiaoling [1 ]
Jiang, Erlie [1 ]
Han, Mingzhe [1 ]
Zhou, Jiaxi [1 ]
Feng, Sizhou [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
关键词
Allogeneic hematopoietic stem cell transplantation; poor graft function; graft rejection; risk factors; treatment; VERSUS-HOST-DISEASE; SPLEEN;
D O I
10.1080/16078454.2022.2042064
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Graft failure (GF) is an intractable complication of transplantation, which can severely affect the efficacy of the graft; however, the characteristics, incidence, and risk factors of primary GF have not been well described. This study aimed to analyze the risk factors and outcomes of primary GF to swiftly identify high-risk patients for GF. Methods We performed a case-control study with a case-control ratio of 1:4 with 869 patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2015 and December 2019 at our center. Results Nineteen (2.19%) patients experienced primary poor graft function (PGF), while eleven (1.27%) patients developed primary graft rejection (GR). Univariate and multivariate logistic analyses identified two independent risk factors for primary PGF: splenomegaly [P = 0.030; odds ratio (OR), 3.486; 95% confidence interval (CI), 1.139 to 13.109], and donor type [non-matched sibling donor (non-MSD)] (P = 0.018; OR, 4.475; 95% CI, 1.289 to 15.537). However, only donor type (non-MSD) was statistically significant (P = 0.020; OR, 19.432; 95% CI, 1.595 to 236.691) for primary GR. The overall survival was significantly lower in the primary PGF (P = 0.001) and GR group (P = 0.000), respectively, compared to the control group. Conclusion GF can significantly affect the overall survival of patients who underwent allo-HSCT, despite its considerably low incidence. A human leukocyte antigen-matched sibling donor should be the first choice for patients undergoing allo-HSCT for the prevention of GF. Moreover, splenomegaly is an independent risk factor for PGF, and caution must be exercised while treating such patients.
引用
收藏
页码:293 / 299
页数:7
相关论文
共 50 条
  • [1] Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation
    Harada, Kaito
    Kimura, Shun-ichi
    Fuji, Shigeo
    Najima, Yuho
    Yakushijin, Kimikazu
    Uchida, Naoyuki
    Onizuka, Makoto
    Ikegame, Kazuhiro
    Yano, Shingo
    Shingai, Naoki
    Matsuoka, Ken-ichi
    Onishi, Yasushi
    Sawa, Masashi
    Takada, Satoru
    Kawakita, Toshiro
    Fukuda, Takahiro
    Kanda, Junya
    Atsuta, Yoshiko
    Nakasone, Hideaki
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (09) : 2183 - 2193
  • [2] Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation
    Kaito Harada
    Shun-ichi Kimura
    Shigeo Fuji
    Yuho Najima
    Kimikazu Yakushijin
    Naoyuki Uchida
    Makoto Onizuka
    Kazuhiro Ikegame
    Shingo Yano
    Naoki Shingai
    Ken-ichi Matsuoka
    Yasushi Onishi
    Masashi Sawa
    Satoru Takada
    Toshiro Kawakita
    Takahiro Fukuda
    Junya Kanda
    Yoshiko Atsuta
    Hideaki Nakasone
    [J]. Bone Marrow Transplantation, 2021, 56 : 2183 - 2193
  • [3] Graft failure after allogeneic hematopoietic stem cell transplantation: Definition and risk factors
    Alcazer, Vincent
    de Latour, Regis Peffault
    Ader, Florence
    Labussiere-Wallet, Helene
    [J]. BULLETIN DU CANCER, 2019, 106 (06) : 574 - 583
  • [4] The incidence, risk factors and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation
    Gao, Fei
    Shi, Jimin
    Luo, Yi
    Tan, Yamin
    Lai, Xiaoyu
    Yu, Jian
    Huang, He
    Zhao, Yanmin
    [J]. BONE MARROW TRANSPLANTATION, 2019, 54 : 249 - 250
  • [5] Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
    Zhao, Yanmin
    Gao, Fei
    Shi, Jimin
    Luo, Yi
    Tan, Yamin
    Lai, Xiaoyu
    Yu, Jian
    Huang, He
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (09) : 1898 - 1907
  • [6] Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure
    Remberger, Mats
    Mattsson, Jonas
    Olsson, Richard
    Ringden, Olle
    [J]. CLINICAL TRANSPLANTATION, 2011, 25 (01) : E68 - E76
  • [7] Risk Factors and Outcomes of ICU Admission Following Allogeneic Hematopoietic Stem Cell Transplantation
    Jamy, Omer Hassan
    Dasher, John
    Chen, Yanjun
    Battles, Kevin D.
    Salzman, Donna
    Di Stasi, Antonio
    Bhatia, Ravi
    Bhatia, Smita
    [J]. BLOOD, 2021, 138 : 1784 - +
  • [8] Graft failure following allogeneic hematopoietic stem cell transplantation: our experience
    Rady, R.
    Abdelkader, A.
    Abdelsalam, M.
    Abdelmohsen, M.
    Ragaay, M.
    Saad, M.
    Abdelaziz, D.
    El Ghamrawy, M.
    Salama, K.
    [J]. BONE MARROW TRANSPLANTATION, 2016, 51 : S587 - S588
  • [9] Salvage Allogeneic Hematopoietic Stem Cell Transplantation for Primary Graft Failure in Children
    Kato, Motohiro
    Matsumoto, Kimikazu
    Suzuki, Ritsuro
    Yabe, Hiromasa
    Inoue, Masami
    Kigasawa, Hisato
    Inagaki, Jiro
    Tauchi, Hisamichi
    Sakamaki, Hisashi
    Kawa, Keisei
    Kato, Koji
    Fukuda, Takahiro
    [J]. BLOOD, 2012, 120 (21)
  • [10] Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation
    Kaito Harada
    Yuho Najima
    Motohiro Kato
    Shigeo Fuji
    Akihito Shinohara
    Hirohisa Nakamae
    Masako Toyosaki
    Miho Ashiarai
    Makoto Onizuka
    Yoshiko Hashii
    Tatsuo Ichinohe
    Yoshiko Atsuta
    Hideki Nakasone
    [J]. International Journal of Hematology, 2022, 116 : 744 - 753